C5 and paroxysmal nocturnal hemoglobinuria: As of 2020, treatments for patients with PNH included the C5 inhibitors eculizumab and ravulizumab, which inhibit formation of the complement-initiated membrane attack complex and consequently prevent intravascular hemolysis.